Payment overview · 2025
General Payments
$172.30
10 reported records · 6 companies
Healthcare provider profile · identity verified
Phillip Poulos, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, GA · NPI 1053422675
Verified facts
What the public records show
CMS Open Payments records show Phillip Poulos, M.D. received $172.30 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.98 | 33.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.35 | 29.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.12 | 11.7% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.66 | 9.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.60 | 7.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.59 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $172.30 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.98 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.35 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1029 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 167 |
| Metformin Hcl | Metformin Hcl | 496 | 146 |
| Lisinopril | Lisinopril | 467 | 132 |
| Losartan Potassium | Losartan Potassium | 309 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 280 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 270 | 73 |
| Gabapentin | Gabapentin | 252 | 82 |
| Famotidine | Famotidine | 240 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 50 |
| Carvedilol | Carvedilol | 222 | 63 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 209 | 38 |
| Omeprazole | Omeprazole | 189 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 78 |
| Furosemide | Furosemide | 186 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 53 |
| Potassium Chloride | Potassium Chloride | 165 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 164 | 49 |
| Glipizide | Glipizide | 153 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 55 |
| Tramadol Hcl | Tramadol Hcl | 139 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 34 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 117 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 33 |
| Atenolol | Atenolol | 103 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 30 |
| Montelukast Sodium | Montelukast Sodium | 90 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 89 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 31 |
| Clonidine Hcl | Clonidine Hcl | 83 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 26 |
| Nifedipine Er | Nifedipine | 81 | 21 |
| Simvastatin | Simvastatin | 81 | 23 |
| Farxiga | Dapagliflozin Propanediol | 80 | 22 |
| Ibuprofen | Ibuprofen | 72 | 35 |
| Eliquis | Apixaban | 67 | 17 |
| Dovato | Dolutegravir Sodium/Lamivudine | 64 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Descovy | Emtricitabine/Tenofov Alafenam | 61 | 11 |
| Trulicity | Dulaglutide | 59 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 12 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 57 | suppressed |
| Spironolactone | Spironolactone | 54 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 27 |
| Allopurinol | Allopurinol | 48 | 14 |
| Darunavir | Darunavir | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Tivicay | Dolutegravir Sodium | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | 17 |
| Naproxen | Naproxen | 42 | 17 |
| Lovastatin | Lovastatin | 41 | 11 |
| Juluca | Dolutegravir/Rilpivirine | 40 | suppressed |
| Ozempic | Semaglutide | 40 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 39 | 11 |
| Isentress | Raltegravir Potassium | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 16 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Ritonavir | Ritonavir | 35 | suppressed |
| Colchicine | Colchicine | 34 | 14 |
| Edurant | Rilpivirine Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Indomethacin | Indomethacin | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Isentress Hd | Raltegravir Potassium | 16 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Prezista | Darunavir | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Etravirine | Etravirine | 14 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172.30 · 10 records | Novo Nordisk Inc | DOVATO, Dexcom G6 Transmitter, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error